Bristol Myers Squibb Receives Full FDA Approval for Opdivo Plus Yervoy in dMMR Colon Cancer

Bristol Myers Squibb today announced that the FDA has granted full approval to nivolumab (Opdivo) plus ipilimumab (Yervoy) as neoadjuvant therapy for the treatment of adults with resectable dMMR colon cancer. The full approval was based on Phase 3 trial data demonstrating a complete pathological response rate of 68%, enabling organ-sparing approaches in many patients. This full approval establishes neoadjuvant immunotherapy as a standard of care in dMMR colon cancer and represents a landmark achievement in cancer treatment.